Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
VOPP1 divergent transcript (VOPP1-DT) refers to a long non-coding RNA (lncRNA) transcribed from the region adjacent to, and in the opposite direction from, the VOPP1 protein-coding gene. Divergent transcription is a common phenomenon at promoters and enhancers in mammalian genomes, producing non-coding RNAs whose abundance and function are often poorly understood. There is no evidence that VOPP1-DT encodes a protein or functions as a receptor, enzyme, or other conventional drug target. It is best classified as a genomic feature that reflects the diversity of non-coding RNA transcription but has not been established as a specific therapeutic target or biomarker[1][3][5]. Summary: - VOPP1-DT is not a protein, receptor, or conventional drug target. - It refers generically to a divergent lncRNA transcript at the VOPP1 locus. - Its functions and disease relevance are undefined, with no supporting evidence for biomarker or drug-target roles. - The name is correct as a non-coding RNA locus, but it is not a target in the pharmaceutical or therapeutic sense[1][3][5].
None known
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on VOPP1 divergent transcript (VOPP1-DT).